Evolving approaches to patients with advanced differentiated thyroid cancer
about
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid CancerMetastatic mechanisms in follicular cell-derived thyroid cancerCurrent status and future perspectives in differentiated thyroid cancerUpdate: the status of clinical trials with kinase inhibitors in thyroid cancerCorrelative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology GroupA phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma.Multikinase inhibitors use in differentiated thyroid carcinoma.Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience.Trends and Predictors of Chemotherapy Use among Thyroid Cancer Patients in the National Cancer Database (2004-2013).External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer.Optimal differentiated thyroid cancer management in the elderly.Selective use of vandetanib in the treatment of thyroid cancer.Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives.Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).Nuclear Molecular and Theranostic Imaging for Differentiated Thyroid Cancer.Molecular pathways associated with aggressiveness of papillary thyroid cancerIncreasing thyroid cancer incidence in Queensland, Australia 1982-2008 - true increase or overdiagnosis?The management of metastatic radioiodine-refractory differentiated thyroid cancer requires an integrated approach including both directed and systemic therapies.Nuclear factor κB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8.Follicular cell-derived thyroid cancer.Overexpression of teneurin transmembrane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma.Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and BeyondThe role of palbociclib in thyroid carcinoma with BRAF mutation
P2860
Q26829349-B80B8596-793E-4C4B-B334-663923FB6712Q27005646-5D8AAC4B-7256-4D8F-B46B-5793D164F187Q27024484-4A0546B4-76FA-43BE-9EC9-5305551D50FDQ33570056-9A589133-49F5-4F15-9F67-2B53302E1A95Q33587905-EF0C3F1A-00E2-438E-B555-ACC7539D1302Q34330748-A1BC05E0-047B-42CA-A91D-BFD6BAE01FF8Q34468149-0D7FE0EB-16E0-43AC-BBAA-5923741B7660Q34660901-EFBCA642-9288-40BB-904D-57C2DA06E4BAQ37010592-92EBA15F-52E4-4FF0-9706-D9E34981086DQ37562871-9A42C5AA-D6AC-4815-8FE9-4F76CFD02549Q38222938-41579977-709A-4343-BA39-2A6FF0BEAA64Q38396892-04A1401B-3B0C-4716-984F-7807CD79440EQ38546474-AB9723AF-979B-4029-8E53-8020BBCFE1B2Q38675367-2A6EF8DD-C99C-4CE9-B3E2-27D348295FF9Q38823954-1F6F0FBB-9681-404C-94CE-41A3EE2A80BEQ38844362-63997352-EC62-498D-833E-8C1B86654021Q38851509-9D55F5AF-BE84-4EA3-942D-2EF282AE1BA6Q39100644-DD76F462-9EA8-4ED5-AA18-D12B0E67271AQ39171721-E1F316A4-13E2-4CC3-AEEC-52C0F9B671D1Q41569294-C9817FC0-413D-40BA-90B9-3F90012FDACEQ41999750-17990D8C-B2B8-4B48-8DCF-89C013E88901Q42095623-49C176E7-802F-4A79-B072-6344CD99BCF6Q48651339-175A18AF-8E1A-4F9B-9319-D91ED339A9A6Q51243316-CE2119DC-F673-4A10-BE5F-D23AC3C98727Q58784257-A0C3CDA2-FFB5-4F2D-9BF8-709ACC6037A1Q58805425-86FE2147-CDD3-485A-B2E9-3E4C37BD553B
P2860
Evolving approaches to patients with advanced differentiated thyroid cancer
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Evolving approaches to patients with advanced differentiated thyroid cancer
@en
type
label
Evolving approaches to patients with advanced differentiated thyroid cancer
@en
prefLabel
Evolving approaches to patients with advanced differentiated thyroid cancer
@en
P2860
P356
P1433
P1476
Evolving approaches to patients with advanced differentiated thyroid cancer
@en
P2093
Bryan R Haugen
P2860
P304
P356
10.1210/ER.2012-1038
P577
2013-04-10T00:00:00Z